vs
Side-by-side financial comparison of Third Coast Bancshares, Inc. (TCBX) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $57.7M, roughly 1.8× Third Coast Bancshares, Inc.). Third Coast Bancshares, Inc. runs the higher net margin — 28.4% vs -29.4%, a 57.8% gap on every dollar of revenue.
Third Coast Bancshares, Inc. is a regional financial holding company headquartered in the U.S. Gulf Coast region. It provides a full suite of commercial and retail banking services including deposit products, business and consumer loans, mortgage services, and wealth management solutions, serving local small and medium-sized enterprises, individual consumers, and community clients across Texas and surrounding areas.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
TCBX vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $57.7M | $103.7M |
| Net Profit | $16.4M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | — | -31.7% |
| Net Margin | 28.4% | -29.4% |
| Revenue YoY | — | 16.9% |
| Net Profit YoY | 20.5% | 3.4% |
| EPS (diluted) | $0.88 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $57.7M | — | ||
| Q4 25 | $56.5M | $103.7M | ||
| Q3 25 | $54.5M | — | ||
| Q2 25 | $52.0M | — | ||
| Q1 25 | $45.9M | — | ||
| Q4 24 | $46.3M | — | ||
| Q3 24 | $42.9M | — | ||
| Q2 24 | $41.7M | — |
| Q1 26 | $16.4M | — | ||
| Q4 25 | $17.9M | $-30.5M | ||
| Q3 25 | $18.1M | — | ||
| Q2 25 | $16.7M | — | ||
| Q1 25 | $13.6M | — | ||
| Q4 24 | $13.7M | — | ||
| Q3 24 | $12.8M | — | ||
| Q2 24 | $10.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 38.1% | -31.7% | ||
| Q3 25 | 41.9% | — | ||
| Q2 25 | 40.5% | — | ||
| Q1 25 | 37.8% | — | ||
| Q4 24 | 38.7% | — | ||
| Q3 24 | 37.9% | — | ||
| Q2 24 | 34.1% | — |
| Q1 26 | 28.4% | — | ||
| Q4 25 | 31.7% | -29.4% | ||
| Q3 25 | 33.1% | — | ||
| Q2 25 | 32.2% | — | ||
| Q1 25 | 29.6% | — | ||
| Q4 24 | 29.7% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 25.9% | — |
| Q1 26 | $0.88 | — | ||
| Q4 25 | $1.02 | $-0.50 | ||
| Q3 25 | $1.03 | — | ||
| Q2 25 | $0.96 | — | ||
| Q1 25 | $0.78 | — | ||
| Q4 24 | $0.80 | — | ||
| Q3 24 | $0.74 | — | ||
| Q2 24 | $0.63 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $650.5M | $456.1M |
| Total Assets | $6.6B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $175.2M | $197.9M | ||
| Q3 25 | $116.4M | — | ||
| Q2 25 | $113.1M | — | ||
| Q1 25 | $219.0M | — | ||
| Q4 24 | $371.2M | — | ||
| Q3 24 | $258.2M | — | ||
| Q2 24 | $241.8M | — |
| Q1 26 | $650.5M | — | ||
| Q4 25 | $531.0M | $456.1M | ||
| Q3 25 | $513.8M | — | ||
| Q2 25 | $496.1M | — | ||
| Q1 25 | $479.8M | — | ||
| Q4 24 | $460.7M | — | ||
| Q3 24 | $450.5M | — | ||
| Q2 24 | $435.0M | — |
| Q1 26 | $6.6B | — | ||
| Q4 25 | $5.3B | $638.1M | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $4.9B | — | ||
| Q4 24 | $4.9B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $50.8M | $-24.8M | ||
| Q3 25 | $20.7M | — | ||
| Q2 25 | $13.9M | — | ||
| Q1 25 | $10.5M | — | ||
| Q4 24 | $35.1M | — | ||
| Q3 24 | $22.0M | — | ||
| Q2 24 | $7.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.84× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 0.77× | — | ||
| Q4 24 | 2.56× | — | ||
| Q3 24 | 1.72× | — | ||
| Q2 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TCBX
| Net Interest Income | $53.6M | 93% |
| Noninterest Income | $4.0M | 7% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
